Recurrent and metastatic female adnexal tumor of probable Wolffian origin

A case report and review of the literature

Qiuhe Chen, MS\textsuperscript{a,b}, Yangmei Shen, MD, PhD\textsuperscript{b,c}, Chuan Xie, MD, PhD\textsuperscript{a,b,*}

Abstract

**Rationale:** Female adnexal tumors of probable Wolffian origin (FATWOs) are rare gynecologic neoplasms arising from the mesonephric duct remnants. Less than 90 cases have been reported in the English literature. Although most cases of FATWO are considered benign, recurrence and metastasis may occur in very few cases during the course of the disease. Due to the small number of recurrent and metastatic FATWO cases, there are no clear recommendations regarding optimal treatment.

**Patient concerns:** A 75-year-old postmenopausal woman, who underwent a mass excision of the right broad ligament three years ago, was found to have a right adnexal mass during a regular postoperative physical examination.

**Diagnoses:** Vaginal ultrasound examination revealed a cystic and solid mass approximately 3.6 $\times$ 4.4 $\times$ 3.8 cm on the right side of the uterus. Three years ago, the mass of the right broad ligament was diagnosed with FATWO in the local hospital. Following extensive immunohistochemistry analysis and after reviewing the histology slides from the primary tumor, the final diagnosis of the mass on the right side of the uterus was recurrent and metastatic FATWO.

**Interventions:** The patient underwent laparoscopic mass excision, hysterectomy and resection of the metastatic lesion in the small intestine, and then she received 6 cycles of docetaxel and carboplatin-based chemotherapy.

**Outcomes:** The disease has recurred three years after the first surgery in the local hospital. After the second surgery followed by systemic chemotherapy, there is no evidence of recurrence with 24 months of follow-up till now.

**Lessons:** FATWO is considered a benign entity. However, a few FATWOs have been shown to behave aggressively. Due to only a few reported cases, there are no comprehensive recommendations regarding the optimal clinical management of recurrent and metastatic FATWOs. Complete surgical resection followed by combination chemotherapy is considered to be the most effective therapy for recurrent and metastatic FATWOs. Chemotherapy with docetaxel plus carboplatin, which is most commonly used in malignant cases, may be effective in the treatment of recurrent and metastatic FATWOs.

**Abbreviations:** CT = computed tomography, FATWO = Female adnexal tumor of probable Wolffian origin, HES = hematoxylin-eosin saffron.

**Keywords:** chemotherapy, female adnexal tumor of probable Wolffian origin, management, prognosis

1. Introduction

Female adnexal tumors of probable Wolffian origin (FATWOs) are rare gynecologic neoplasms derived from mesonephric duct remnants of the female genital tract, with >90 cases reported in the English literature.\textsuperscript{1} FATWOs were first reported by Kariminejad and Scully in 1973, and they regarded the tumor as a nonmalignant neoplasm despite the presence of mitotic activity and capsular invasion.\textsuperscript{2,3} These tumors are considered to have low malignant potential over time, as only a few cases have been found to relapse and metastasize and most of these tumors have a benign course.\textsuperscript{1,3} It has been reported that recurrence and metastasis occur in approximately 11\% of cases and they may occur as early as 2 years after diagnosis.\textsuperscript{3} Due to the few reported cases, there are no clear recommendations regarding the optimal management of recurrent and metastatic FATWOs. Here, we report a case of recurrent and metastatic FATWO arising from the broad ligament and review the literature on the optimal management and prognosis of this disease, to provide clinicians with a better understanding and management of the disease.

2. Case presentation

Ethical approval and patient consent were acquired and recorded in the patient medical record with witness signature. All ethical
approval and consent procedures were approved by the Medical Ethical Committee of West China Second University Hospital, Sichuan University.

A 75-year-old post-menopausal G3P2 Chinese woman originally presented in 2015 with a right adnexal mass. At laparotomy, she was noted to have a mass approximately 8cm in diameter arising from the broad ligament. There was no evidence of any other pelvic or abdominal disease. The patient underwent a simple mass excision combined with prophylactic bilateral adnexectomy in a local hospital. After consultation with two different external expert pathologists, the mass was suggested to be a FATWO. The patient had a good recovery without complications. In October 2018, vaginal ultrasound at our institution during routine follow-up showed a cystic and solid mass approximately 3.6\(\times\)4.4\(\times\)3.8cm in the right adnexal area. The patient did not have vaginal bleeding, abdominal pain, abdominal distension or other discomfort. There was no family history of breast or ovarian cancer. On physical examination, except for the mass on the right side of the uterus, no other abnormalities were recorded. Laboratory test results, including blood cell counts and tumor markers such as cancer antigen-125, were all within the normal ranges. Pelvic computed tomography (CT) suggested a cystic and solid mass about 5\(\times\)4cm on the right side of the uterus, with a regular shape and close contact with the wall of the uterus.

After a detailed explanation and comprehensive counseling regarding the advantages of a single surgical intervention, laparoscopy was performed. At diagnostic laparoscopy, gross examination showed that there was a solid and cystic mass approximately 5\(\times\)4cm in size on the right side of the pelvic cavity, which was densely adhered to the posterior leaf of the right broad ligament, the right posterior lateral wall of the uterus and the small intestine. Intraoperative findings showed no obvious ascites fluid. Except for the right posterior lateral wall of the uterus, the posterior leaf of the right broad ligament and part of the small intestine, no obvious tumor invasion was observed in other sites of the abdominal and pelvic cavity. Resection of the tumor mass combined with a total hysterectomy was performed, and peritoneal washing was also undertaken during surgery. The postoperative course was uneventful and the patient was discharged on day 5 after surgery.

Gross examination of the excised specimen showed that the tumor mass was mainly solid and partly cystic, and the cut surface of the solid component was gray-white. Pathological findings revealed that the neoplastic cells were diffuse shaped by solid, tubular, and sieve-like pattern, with some cystic changes. Local areas of fibrous stroma divided the tumor into lobules. Most of the cells were square or columnar; the round or oval nuclei were cytologically bland with fine, evenly dispersed chromatin, an absence of discernible nucleoli and a low mitotic index (Fig. 1). Immunohistochemical stainings for CK7, Vimentin, EMA, TTF-1, CD10, Pax-8, Pax-2, P16, and CA125 were positive and ER, PR, AR, CEA, \(\alpha\)-inhibin, CD56, and CK20 were negative. The Ki-67 index of the tumor was around 60%. Following extensive immunohistochemistry analysis and reviewing the histology slides from the primary tumor, the final diagnosis was recurrent and metastatic FATWO. According to the current ovarian cancer staging system of the International Federation of Gynecology and Obstetrics (FIGO, 2017), this tumor was staged as IIIC.

A medical oncologist was consulted, and additional chemotherapy was recommended. The patient received adjuvant chemotherapy with 6 cycles of docetaxel (80mg/m\(^2\)) and carboplatin (300mg/m\(^2\)) 3 weeks after the second surgery. The patient was regularly reviewed for chest and abdominal CT scans and tumor markers; there was no evidence of recurrence at 2 years after the second surgery. We will continue to follow-up this patient.

3. Discussion

FATWOs are extremely uncommon tumors with low malignant potential and are believed to derive from mesonephric remnants. To date, approximately 90 cases of FATWO have been reported. Although most cases of FATWO exhibit a benign clinical behavior, a few cases have been shown to be aggressive. In recent
| Case | Author                  | Age, y | Primary site          | Operation                                                                 | Stage | Site of metastasis or recurrence | Treatment after recurrence          | Follow-up                     |
|------|-------------------------|--------|-----------------------|---------------------------------------------------------------------------|-------|---------------------------------|------------------------------------|------------------------------|
| 1    | Taxy and Battifora, 1976 | 41     | Right broad ligament  | 1. H, BSO  
2. Abdominal exploration  
3. Tumor implants removal | I     | Pelvis cobalt irradiation | Liver | NA | METS, 6 y   |
| 2    | Buntine, 1979           | NA     | Vaginal apex          | NA | III | Radiotherapy           | NA | NA | NED, 15 mo |
| 3    | Abbott et al, 1981      | 18     | Right mesosalpinx     | 1. STR  
2. BSO, omentectomy  
3. Tumor implants removal | I     | NA | 1. Pelvis and peritoneum  
2. Peritoneum, omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 1 y |
| 4    | Hughesdon, 1982         | 79     | Left ovary            | BSO | I | No | 1. Omentum, peritoneum,  
retroperitoneal mass  
2. Omentum at the hepatic  
flexure  
3. Right liver | NA | NA | DOD, 1 y |
| 5    | Young and Scully, 1983  | 64     | NA                    | BSO, omentectomy, subtotal  
colocutary | III | NA | 1. Pelvis radiation  
2. Abdomen radiation  
3. REC, 7 y | NA | NA | NED, 5 y since the  
third recurrence. |
| 6    | Young and Scully, 1983  | 52     | NA                    | H, BSO | IAI | NA | 1. Pelvis and peritoneum  
2. Omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 1 y |
| 7    | Brescia et al, 1984     | 23     | Retroperitoneal mass  | 1. STR  
2. Mass resection  
3. Right hepatectomy | I | NA | 1. Pelvis and peritoneum  
2. Omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 1 y |
| 8    | Prasad et al, 1992      | 47     | NA                    | NA | III | NA | 1. Pelvis and peritoneum  
2. Omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 1 y |
| 9    | Daya et al, 1993        | 20     | Right paravaginal mass | 1. STR  
2. Small biopsy  
3. Laparotomy | I | NA | 1. Previous surgery site  
2. Right paravaginal area | Pelvis | NA | 2. REC, 2 y |
| 10   | Daya, 1994              | 81     | Right broad ligament  | NA | NA | Extensive omentum       | NA | NA | DOD, 3 mo |
| 11   | Sheyn et al, 2000       | 60     | Right broad ligament  | H, BSO, omentectomy, subtotal  
colocutary | III | NA | 1. Pelvis and peritoneum  
2. Omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 3 y |
| 12   | Ramirez et al, 2002     | 38     | Right paratubal nodule | 1. H, nodule removal  
2. Mass resection, BSO,  
omentectomy, peritoneal  
mesothelial masses  
excision and appendectomy | I | NA | 1. Pelvis and peritoneum  
2. Omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 4 y |
| 13   | Ramirez et al, 2002     | 71     | Pelvis                | NA | III | NA | 1. Pelvis and peritoneum  
2. Omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 4 y |
| 14   | Halashtia and Ali, 2004 | 34     | Right fallopian tube  | NA | NA | Extensive omentum       | NA | NA | DOD, 3 mo |
| 15   | Attalah et al, 2004     | 27     | Left broad ligament   | 1. STR  
2. BSO, omentectomy, pelvic  
and para-aortic lymph node  
deissection  
3. Tumor implants removal | I | NA | 1. Pelvis and peritoneum  
2. Omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 3 y |
| 16   | Steed et al, 2004       | 15     | Right broad ligament  | 1. STR  
2. Tumor removal  
3. Debulking surgery  
4. H, BSO, upper vaginectomy,  
large and small bowel  
resections, and  
debulking surgery | I | NA | 1. Pelvis and peritoneum  
2. Omentum, bowel  
serosa, and the left  
hemidiaphragm | Liver | NA | 2. METS, 3 y |

(continued)
Table 1 (continued).

| Case  | Author                   | Age, y | Primary site               | Operation                                                                 | Stage | Treatment after surgery | Site of metastasis or recurrence | Treatment after recurrence | Follow-up          |
|-------|--------------------------|--------|----------------------------|---------------------------------------------------------------------------|-------|-------------------------|--------------------------------|--------------------------|-------------------|
| 17    | Sivridis et al., 2005[17]| 76     | Right broad ligament       | H, BSO                                                                    | III   | No                      | Peritoneum                      | No                       | DOD, 4 mo         |
| 18    | Tamiolakis and Anastasiadis, 2006[18] | 75     | Right ovary                | A right ovary and broad ligament resection                              | NA    | Cisplatin–cytoxan chemotherapy | Left broad ligament             | NA                       | METS, 2 y         |
| 19    | Deen et al., 2007[19]    | 81     | Right ovary                | H, BSO, omentectomy                                                      | I     | No                      | Right adnexa                    | No                       | NED, 7 mo         |
| 20    | Lesin and Forko-Ilic, 2009[20] | 60     | Right adnexa               | 1. H, BSO, omentectomy                                                  | IA    | No                      | Vaginal cuff                    | No                       | 1. METS, 6 y      |
| 21    | Syriac et al., 2011[21]  | 38     | Right broad ligament       | 1. STR                                                                   | I     | No                      | Left ovary                      | Gloevec                  | 1. METS, 3 y      |
| 22    | Liu, 2011[22]            | 24     | Left broad ligament        | 1. STR                                                                   | III   | NA                      | 1. Omentum                      | N                        | NA                |
| 23    | Deshimaru et al., 2014[23] | 30     | Right fallopian tube       | 1. USO, tumorectomy                                                      | NA    | 1. Paclitaxel and carboplatin | 2. Imitinotecan and gemcitabine | 1. Bowel serosa, omentum, and left ovary. Pouch of Douglas | 1. METS, 4 mo      |
| 24    | Nakamura et al., 2014[24] | 69     | NA                         | NA                                                                       | NA    | NA                      | NA                             | NA                       | RECR, 1 y         |
| 25    | Kwon et al, 2016[25]     | 26     | Left ovary                 | H, BSO, omentectomy and pelvic lymph node dissection                    | I     | No                      | 1. Vaginal stump                 | Paclitaxel and carboplatin  | 1. METS, 9 mo      |
| 26    | Hong et al., 2017[26]    | 50     | Bilateral ovaries          | H, BSO, omentectomy, pelvic and para-aortic lymph node dissection        | NA    | NA                      | 2. Uterine serosa               | NA                       | 2. LFU            |
| 27    | Qiu et al, 2017[27]      | 53     | Left mesosalpinx           | 1. H, BSO, tumor resection and omentectomy                              | NA    | No                      | 1. Omentum, mesentery, and peritoneum | 1. Cisplatin and docetaxel; oxaliplatin and docetaxel | 1. METS, 2 y      |
| 28    | Wakayama et al, 2017[28] | 37     | Left fallopian tube        | 1. USO, pelvic lymph node sampling and omental biopsy                   | II    | No                      | 2. Right lung, right liver and left adrenal gland | 2. Continuous renal replacement and hepatoprotection therapy | 2. METS, 2 mo      |
| 29    | Present case             | 75     | Right broad ligament       | Lately: H, intestinal adhesion lysis                                    | III   | Docetaxel and carboplatin                      | Bowel serosa                  | No                       | NED, 2 y          |

BSO = bilateral salpingo-oophorectomy, DOD = dead of disease, H, BSO = hysterectomy with bilateral salpingo-oophorectomy, LFU = lost to follow-up, METS = metastasis, NED = no evidence of disease, RECR = recurrence, STR = simple tumor resection, USO = unilateral salpingo-oophorectomy.
years, some metastatic and recurrent cases have been reported. We searched the PubMed and GenMedicine databases using the keywords “Wolfian origin,” “malignant,” and “metastatic,” and found 26 studies published between 1976 and 2017.[1,4–26] These studies involved 28 patients (Table 1). According to the results in Table 1, women of all ages are likely to develop malignant FATWO, and the age of the patients diagnosed with FATWO ranged from 15 to 81 years. However, most patients were aged >50 years at the time of initial diagnosis. FATWO mainly arises in the broad ligament and occasionally occurs in the mesosalpinx, ovary, and fallopian tube, but rarely occurs in the retroperitoneum and paravaginal region. The omentum and peritoneum are the most frequent metastatic sites, and other common metastatic sites are the liver, bowel serosa, lung, and paravaginal region. The median time to recurrence and metastasis was 33.5 months with a range of 4 to 96 months. Most recurrent and metastatic diseases developed in patients who were initially treated with tumor resection alone.

The clinical manifestations of FATWOs are varied; patients with FATWOs may have abdominal pain or irregular vaginal bleeding as their main symptoms, or feel a palpable mass in the abdomen when the tumor is large enough. Many patients are asymptomatic, and the tumors are found incidentally during imaging studies or laparoscopy for other gynecological disease. Histologically, FATWOs can exhibit a variety of growth patterns, including tubular, sieve-like, solid and diffuse in various combinations. The tubal lumen and sieve-like spaces often contain eosinophilic, colloid-like, PAS-positive substance.[15] Hence, early diagnosis may be difficult. Sirvidis et al.[17] combined the malignancies described earlier and proposed diagnostic criteria for malignant FATWO: tumors >10 cm in diameter, obvious hypercellularity, capsular invasion, capsular rupture and verifiable tumor implants and metastases. Fortunately, most FATWOs exhibit a benign clinical behavior.

Due to the rarity of FATWO and the few reported cases, optimal management has not yet been established. However, complete tumor resection, including hysterectomy, bilateral salpingo-oophorectomy, and debulking surgery, is the preferred treatment for FATWO. Most tumor relapses occur in patients initially treated with conservative procedures such as cystectomy or simple tumor resection.[12,13,20] Although there are some case reports of remission or partial remission following specific adjuvant therapy, the exact effect of radiotherapy, chemotherapy, hormone therapy, and molecular-targeting therapy on malignant FATWO remains to be clarified.

It is imperative to institute appropriate treatment strategies in patients with malignant FATWO.

Multiple chemotherapy regimens have been used to treat recurrent and metastatic FATWO, such as paclitaxel/cisplatin/cyclophosphamide,[15,16] etoposide/ifosfamide/cisplatin,[16] cyclophosphamide/doxorubicin/cis-platinum,[15] and cisplatin/oxaliplatin/docetaxel[27] (Table 1); however, the effects were not satisfactory. A recent study[28] showed that carboplatin and paclitaxel combination therapy produced a good response in patients with recurrent and metastatic FATWO following the failure of imatinib treatment. Atallah et al.[15] reported a patient with progesterone receptor-positive FATWO with tumor recurrence after pregnancy. The patient received paclitaxel plus cisplatin chemotherapy, which induced temporary disease stabilization. Qiu et al.[27] reported a patient with recurrent FATWO who was treated with cisplatin/oxaliplatin/docetaxel chemotherapy, which resulted in side effects and the patient had recurrent disease 2 months after the second surgery and died ultimately. In our patient, a good response to platinum-based chemotherapy was observed without side effects. In addition, there was no evidence of recurrence at 2 years’ follow-up after the second surgery, indicating that combination chemotherapy with docetaxel plus carboplatin may be effective for treating recurrent and metastatic FATWOs. However, further studies are needed to determine the effectiveness of this chemotherapy regimen.

The prognosis of FATWO is independent of clinical presentation and histological features, and recurrence can still occur in the absence of aggressive histological findings.[15] It was reported that the median recurrence time for FATWOs was 48 months with a range of 13 to 96 months, and liver and lung were the most frequent metastatic sites.[13,20] According to the findings shown in Table 1, the median time to recurrence and metastasis was 33.5 months, ranging from 4 to 96 months, and some cases experienced multiple relapses during this time. The most common site of tumor metastasis is the omentum and peritoneum, followed by the liver, bowel serosa, lung and paravaginal region. Only 1 case metastasized to the appendix. The presence of necrosis, capsular invasion, a high number of mitoses, cellular pleomorphism, immunohistochemical positivity for CD117 and, probably, overexpression of Ki-67 are the currently known properties of FATWOs with malignant potential.[14]

4. Conclusions

FATWOs are rare gynecologic neoplasms of low-malignant potential which are considered to derive from mesonephric remnants. Although most cases of FATWO have a benign course, some have the potential for recurrence and metastasis, and a few patients have died of the disease within a short time. Due to only a few reported cases, there are no distinct recommendations regarding the optimal management of recurrent and metastatic FATWOs. We reviewed previous cases to determine the best treatment protocol. Complete surgical resection with hysterectomy, bilateral adnexectomy, and debulking of the tumor, followed by combination chemotherapy is considered to be the most effective therapy for recurrent and metastatic FATWOs. Chemotherapy with docetaxel plus carboplatin, which is most commonly used in malignant cases, may be effective in the treatment of recurrent and metastatic FATWOs.

Author contributions

Conceptualization: Qiuhe Chen, Chuan Xie.
Data curation: Qiuhe Chen, Yangmei Shen, Chuan Xie.
Formal analysis: Qiuhe Chen.
Investigation: Qiuhe Chen, Yangmei Shen, Chuan Xie.
Software: Qiuhe Chen, Chuan Xie.
Methodology: Yangmei Shen, Chuan Xie.
Writing – original draft: Qiuhe Chen, Chuan Xie.
Writing – review & editing: Qiuhe Chen, Chuan Xie.

References

[1] Taxy JB, Battifora H. Female adnexal tumor of probable wolfian origin. Cancer 1976;37:2349–54.
[2] Karimincjad MH, Scully RE. Female adnexal tumor of probable wolfian origin—a distinctive pathologic entity. Cancer 1973;31:671–27.
[3] Shalaby A, Shenoy V. Female adnexal tumor of probable Wolfian origin: a review. Arch Pathol Lab Med 2019;124–8.
Buntine DW. Adenocarcinoma of the uterine cervix of probable Wolfian origin. Pathology 1979;11:713–8.

Abbott RL, Barlogie B, Schmidt WA. Metastasizing malignant juxtaovarian tumor with terminal hypercalcemia: a case report. Cancer 1981;48:860–5.

Hughesdon PE. Ovarian tumours of Wolfian or allied nature: their place in ovarian oncology. J Clin Pathol 1982;35:526–35.

Young RH, Scully RE. Ovarian tumors of probable Wolfian origin: a report of 11 cases. Am J Surg Pathol 1983;7:125–35.

Prasad CJ, Ray JA, Kessler S. Female adnexal tumor of Wolfian origin. Arch Pathol Lab Med 1992;116:189–91.

Daya D, Murphy J, Simon G. Paravaginal female adnexal tumour of probable Wolfian origin. Am J Clin Pathol 1993;101:275–8.

Daya D. Malignant female adnexal tumor of probable Wolfian origin with review of the literature. Arch Pathol Lab Med 1994;118:89–91.

Sheyn I, Mira JL, Bejarano PA, et al. Metastatic female adnexal tumor of probable Wolfian origin: a case report and review of the literature. Arch Pathol Lab Med 2000;124:431–4.

Ramirez PT, Wolf JK, Malpica A, et al. Wolfian duct tumors: case reports and review of the literature. Gynecol Oncol 2002;86:225–30.

Halushka MK, Ali SZ. Pathologic Quiz case. A 34-year-old woman with an inguinal mass. Arch Pathol Lab Med 2004;128:1301–2.

Atallah D, Rouzier R, Voutsadakis I, et al. Malignant female adnexal tumor of probable Wolfian origin relapsing after pregnancy. Gynecol Oncol 2004;95:402–4.

Steed H, Oza A, Chapman WB, et al. Female adnexal tumor of probable Wolfian origin: a clinicopathological case report and a possible new treatment. Int J Gynecol Cancer 2004;14:546–50.

Sivridis E, Giatromanolaki A, Koutlaki N, et al. Malignant female adnexal tumour of probable Wolfian origin: criteria of malignancy. Histopathology 2005;46:716–8.

Tamiolakis D, Anastasiadis P. Metastatic female adnexal tumour of probable Wolfian origin. A histocytopathological correlation. Cytopathology 2007;18:264–6.

Deen S, Duncan TJ, Hammond RH. Malignant female adnexal tumors of probable Wolfian origin. Int J Gynecol Pathol 2007;26:383–6.

Lesin J, Forko-Ilic J, Plavec A: management of Wolfian duct tumor recurrence without chemotherapy. Arch Gynecol Obstet 2009;280:855–7.

Syriac S, Durie N, Kesterson J, et al. Female adnexal tumor of probable Wolfian origin (FATWO) with recurrence 3 years post surgery. Int J Gynecol Pathol 2011;30:231–5.

Liu Y, Metastatic female adnexal tumor of possible Wolfian origin (FATWO) of the appendix demonstrated by FDG PET/CT: The first reported case. Clin Nucl Med 2011;36:136–7.

Deshimaru R, Fukunaga T, Sato T, et al. A case of metastatic female adnexal tumor of probable Wolfian origin. Gynecol Oncol Rep 2014;10:22–4.

Nakamura K, Nakayama K, Miura H, et al. Malignant female adnexal tumor of Wolfian origin (FATWO) positive for CD56: a possible diagnostic role for the biomarker. Eur J Gynaecol Oncol 2014;35:590–3.

Kwon MJ, Yun MJ, Kim MK. A female adnexal tumor of probable Wolfian origin showing positive O-6-methylguanine-DNA methyltransferase methylation. Obstet Gynecol Sci 2016;59:328–32.

Hong S, Cui J, Li L, et al. Malignant female adnexal tumor of probable Wolfian origin: case report and literature review. Int J Gynecol Pathol 2018;37:331–7.

Qiu T, Teng Y, Tong J, et al. Recurrent female adnexal tumor of probably Wolfian origin: a case report. Taiwan J Obstet Gynecol 2017;56:382–4.

Wakayama A, Matsumoto H, Aoyama H, et al. Recurrent female adnexal tumor of probable Wolfian origin treated with debulking surgery, imatinib and paclitaxel/carboplatin combination chemotherapy: a case report. Oncol Lett 2017;13:3403–8.